

A challenge : Bisolvon meets, at mucous gland level, the challenge of the thick, tenacious, non-purulent sputum so characteristic of the chronic bronchitic.

Contributors

Boehringer Ingelheim, Ltd.

Publication/Creation

Isleworth, Middlesex : Boehringer Ingelheim Limited, 1968.

Persistent URL

<https://wellcomecollection.org/works/ppz63xbn>


License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>





Bisolvon meets, at mucous gland level, the challenge of the thick, tenacious, non-purulent sputum so characteristic of the chronic bronchitic.

Important
If a patient reports little or no response it may be because his sputum has become infected and therefore green and purulent during the treatment period. In this case your usual antibiotic should be given concurrently with Bisolvon.

Here is our challenge to you:

Select your two worst bronchitic patients with non-infected sputum and put them on Bisolvon 8 mg. t.d.s. for 2 weeks. At the end of this time they will have experienced the full clinical benefits of Bisolvon therapy—a smaller amount of a watery secretion which is much easier to expectorate.

Bisolvon®

Composition
N-cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)-amine hydrochloride

Presentation
Yellow, compressed tablets with "B" on one side, the Conway symbol on the other, each containing 8 mg. Yellow elixir, containing 4 mg in 5 ml (with 13.5 mg chlorbutol).

Indications
Chronic bronchitis, during exacerbations may be combined with antibiotic therapy. Other conditions in which tenacious sputum is a problem.

Contra-indications
There are no absolute contra-indications, but in patients with gastric ulceration relative caution should be observed in the use of Bisolvon tablets and elixir.

Prediction

Although no anti-bacterial activity is conclusively attributable to Bisolvon, the findings of one investigator strongly suggest that the drug retards the development of colonies of tubercle bacilli. When a patient under treatment for tuberculosis is receiving Bisolvon, therefore sputum cultures for tubercle bacilli should be continued for at least three months before a negative report may be assumed.

Side-effects

Occasional gastro-intestinal side-effects may occur but these are almost invariably mild. In a very small number of patients a transient rise in serum transaminase levels may be seen during treatment with Bisolvon. Despite continuation of the drug, the transaminase levels fall again, even in those patients in whom there pre-exists some impairment of hepatic function.

Dosage

Adults
Tablets 3 three times daily.
Elixir Two 5 ml spoonfuls three times daily.
Children 5-10
Tablets 1 four times daily.
Elixir One 5 ml spoonful four times daily.
Children under 5
Tablets 1 twice daily.
Elixir One 5 ml spoonful twice daily.

Packs
Tablets, containers of 20 and 250.
Elixir, bottles of 200 ml and 1 litre.

Price
The average daily cost for an adult is:
Basic NHS cost (U.K. only) - 1s. 0/6d. for tablets.
Basic NHS cost (U.K. only) - 1s. 8/6d. for elixir.

Further information is available on request



Boehringer Ingelheim Limited
Isleworth, Middlesex